Supernus to Participate in Two Upcoming Investor Conferences
06 mars 2024 16h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
28 févr. 2024 16h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
27 févr. 2024 16h05 HE
|
Supernus Pharmaceuticals, Inc.
Fourth quarter 2023 net sales of Qelbree® increased 97% to $46.4 million compared to fourth quarter 2022; Full year 2023 net sales of Qelbree increased 129% to $140.2 million compared to full year...
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
13 févr. 2024 16h05 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
05 févr. 2024 08h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Third Quarter 2023 Financial Results
08 nov. 2023 16h05 HE
|
Supernus Pharmaceuticals, Inc.
Raises full year 2023 adjusted operating earnings (non-GAAP)(1) guidance range to $95 million to $110 million from previous range of $75 million to $100 millionTotal revenues (GAAP) of $153.9 million...
Supernus to Participate in the Jefferies London Healthcare Conference
07 nov. 2023 16h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
02 nov. 2023 07h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
25 oct. 2023 16h15 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
16 oct. 2023 17h34 HE
|
Supernus Pharmaceuticals, Inc.
Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with...